Objective: This study was conducted to investigate the effects of orally administered apigenin on the pharmacokinetics of venlafaxine (VEN) in rats and on the metabolism of VEN in human and rat liver microsomes in vitro. Methods: Ten healthy male SD rats were randomly divided into 2 groups: A group (control group), B group (a single dose of 250 mg/kg apigenin). A single dose of 20 mg/kg VEN was administered orally 30 min after administration of apigenin (250 mg/kg). VEN plasma levels were measured by HPLC with fluorescence detection, and pharmacokinetic parameters were calculated by DAS 3.0 software. Results: The single dose of 250 mg/kg apigenin significantly increased the AUC0-t of VEN by 40.9% (p < 0.05) and obviously increased the peak plasma concentration (Cmax) of VEN (p < 0.05). Furthermore, apigenin showed inhibitory effect on human and rat microsomes and the IC50 of apigenin was 58.37 and 25.73 μmol/l, respectively. Conclusions: Our results indicated that an intake of apigenin could increase VEN plasma levels and some of its pharmacokinetic parameters (AUC, Tmax). Thus, more attention should be paid when VEN was administrated combined with apigenin.

Keywords:
Venlafaxine, Apigenin, Drug interaction, Metabolism, Pharmacokinetics
1.
Bolden-Watson C, Richelson E: Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-1029.
2.
Oscarson M: Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine. Clin Chem Lab Med 2003;41:573-580.
3.
Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM: Biochemical, neurophysiological, and behavioral effects of Wy-45,030, an ethyl cyclohexanol derivative. Drug Dev Res 1991;23:191-193.
4.
Beara IN, Jovin ED, Balog KJ, Anackov GT, Orcić DZ, Mimica-Dukić NM: Plantain (Plantago L.) species as novel sources of flavonoid antioxidants. J Agric Food Chem 2009;57:9268-9273.
5.
Hodek P, Trefil P, Stiborová M: Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact 2002;139:1-21.
6.
Jiang HD, Fang WJ, Fu XC, Liu FL, Hu YZ: Relationships between structure and activity for flavonoids to lipid peroxidation in liver microsomes from rat. Chem J Chin Univ 2003;24:2221-2223.
7.
Qiu Y, Liu Q, Beta T: Antioxidant activity of commercial wild rice and identification of flavonoid compounds in active fractions. J Agric Food Chem 2009;57:7543-7551.
8.
Yagura T, Motomiya T, Ito M, Honda G, Iida A, Kiuchi F, Tokuda H, Nishino H: Anticarcinogenic compounds in the Uzbek medicinal plant, Helichrysum maracandicum. J Nat Med 2008;62:174-178.
9.
Du W, Sun C, Liang Z, Han Y, Yu J: Antibacterial activity of hypocrellin A against Staphylococcus aureus. World J Microbiol Biotechnol 2012;28:3151-3157.
10.
Wang L, Wang Z, Xia MM, Wang YY, Wang HY, Hu GX: Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro. Can J Physiol Pharmacol 2014;92:961-964.
11.
Liu XY, Xu T, Li WS, Luo J, Geng PW, Wang L, Xia MM, Chen MC, Yu L, Hu GX: The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int 2013;2013:789184.
12.
Song M, Hong M, Lee MY, Jee JG, Lee YM, Bae JS, Jeong TC, Lee S: Selective inhibition of the cytochrome P450 isoform by hyperoside and its potent inhibition of CYP2D6. Food Chem Toxicol 2013;59:549-553.
13.
Ho PC, Saville DJ, Wanwimolruk S: Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 2001;4:217-227.
14.
Wang Z, Sun W, Huang CK, Wang L, Ia MM, Cui X, Hu GX, Wang ZS: Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes. Drug Dev Ind Pharm 2015;41:613-616.
15.
Arsenault-Lapierre G, Kim C, Turecki G: Psychiatric diagnoses in 3275 suicides: a meta-analysis. BMC Psychiatry 2004;4:37.
16.
Cavanagh JT, Carson AJ, Sharpe M, Lawrie SM: Psychological autopsy studies of suicide: a systematic review. Psychol Med 2003;33:395-405.
17.
Zheng P, Gao HC, Qi ZG, Jia JM, Li FF, Chen JJ, Wang Y, Guo J, Melgiri ND, Xie P: Peripheral metabolic abnormalities of lipids and amino acids implicated in increased risk of suicidal behavior in major depressive disorder. Metabolomics 2012;9:688-696.
18.
Khanfar M, Sheikh Salem M, Kaddour F: Preparation of sustained-release dosage form of Venlafaxine HCl using liquisolid technique. Pharm Dev Technol 2014;19:103-115.
19.
Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM: Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996;41:149-156.
20.
le Coutre P, Kreuzer KA, Pursche S, Bonin Mv, Leopold T, Baskaynak G, Dörken B, Ehninger G, Ottmann O, Jenke A, Bornhäuser M, Schleyer E: Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004;53:313-323.
21.
Nebot N, Crettol S, d'Esposito F, Tattam B, Hibbs DE, Murray M: Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol 2010;161:1059-1069.
22.
Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I: Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev 2013;39:773-783.
23.
Laurenzana EM, Weis CC, Bryant CW, Newbold R, Delclos KB: Effect of dietary administration of genistein, nonylphenol or ethinyl estradiol on hepatic testosterone metabolism, cytochrome P-450 enzymes, and estrogen receptor alpha expression. Food Chem Toxicol 2002;40:53-63.
24.
Meyer H, Bolarinwa A, Wolfram G, Linseisen J: Bioavailability of apigenin from apiin-rich parsley in humans. Ann Nutr Metab 2006;50:167-172.
25.
Kim HJ, Lee SB, Kim HM, Park SK, Dong MS, Park YI: Effects of hydroxyl group numbers on the B-ring of 5,7-dihydroxyflavones on the differential inhibition of human CYP 1A and CYP1B1 enzymes. Arch Pharm Res 2005;28:1114-1121.
26.
Chaudhary A, Willett KL: Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John's wort. Toxicology 2006;217:194-205.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.